>R&D>Research Alliances

Research Alliances

In recent years, pharmaceutical discovery has come to require a combination of technologies from a number of specialized fields. While continuing to improve its own R&D capabilities, Takeda actively pursues alliances with other pharmaceutical manufacturers, biotechnology companies, universities, and other research institutions to efficiently introduce key technologies.

Research Alliances with overseas research organizations and companies

Partner	Country	Research subject	Schedule
Oxford Centre for Diabetes, Endocrinology and Metabolism	U.K.	Partnership with Oxford Diabetes Centre	2002/4-
XOMA Ltd.	U.S.	Joint research on discovery, development and production technologies of monoclonal antibody	2006/11-
LG Life Sciences	S. Korea	Joint collaboration on anti-obesity drugs	2007/3-2012/8
Alnylam Pharmaceuticals, Inc.	U.S.	Collaboration for Discovery and Development of RNAi Therapeutics	2008/5-2013/5
Seattle Genetics	U.S.	Research collaboration on Antibody-Drug Conjugate	2009/3-
University of Washington	U.S.	Joint collaboration on anti-obesity drugs	2009/3-2013/3
CellCentric	U.K.	Exclusive licensing of one of the CellCentric's epigenetics projects for the development and commercialization in oncology field	2010/2-
Dimerix	Australia	Research collaboration on searching of GPCR for development of products	2010/3-
BC Cancer Agency	Canada	Research collaboration for discovery of novel candidate targets for cancer treatment	2010/3-2013/3
University College London	U.K.	Research collaboration on development of novel cancer treatment	2010/3-2014/3
University College London	U.K.	Research collaboration in ophthalmologic disease	2010/3-2013/3
Metabolex, Inc.	U.S.	Research collaboration on evaluation and validation of protein targets for development of biological products	2010/4-2013/3
Sage Bionetworks	U.S.	Research collaboration on discovering effective therapeutic targets for Central Nervous System (CNS) disease	2010/11- 2014/11
Florida Hospital, Sanford-Burnham Medical Research Institute	U.S.	Research collaboration to target obesity	2010/12- 2015/2
Zinfandel Pharmaceuticals	U.S.	Licensing Agreement for Alzheimer's Disease Biomarker TOMM40 for the risk of Alzheimer's disease	2010/12-
Heptares Therapeutics	U.K.	Drug discovery collaboration focused on GPCR linked to CNS disorders	2011/4-2013/3
Samyang Corporation	S.Korea	Joint research on novel DDS platform technology for RNAi therapeutics	2011/4-2013/3
Structural Genomics Consortium	Canada	Participation in consortium to advance basic research on selected drug targets based on three-dimensional structures of human proteins	2011/7-2015/6 * Takeda joined 2012/4
BC Cancer Agency	Canada	Research collaboration to explore new drug targets based on gene analysis	2012/8-2015/7
Advinus Therapeutics	India	Discovery collaboration focused on novel targets for marjor therapeutic areas, including Inflammation, CNS, and Metabolic diseases	2012/10-2015/9
Resolve Therapeutics	U.S.	Collaboration to develop compounds for the treatment of Systemic Lupus Erythematosus (SLE)	2013/2-

Research Alliances with domestic research organizations and companies

Partners	Research subject	Schedule
Kirin Brewery Company Ltd. (Now Kyowa Hakko Kirin Ltd.)	Licensing-in of the human antibody technology	2003/7-
Kyoto University	Research collaboration for basic and clinical research project of discovering treatments for obesity and schizophrenia based on CNS control	2011/1-2016/3
Osaka University	Joint research on development of platform for practical application and commercialization of nano-particle vaccines	2012/2-2015/1